Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | — | OT |
Posttransplant HBV vaccine completion with HBsAb testing. HBsAb < 10 IU/L. = 5 (71); This literature marketed report has been received from the authors of the published article and refers to a 71-year-old female adult patient. The patient's medical history included lung transplantation with no acute rejection. The patient's concurrent conditions were not reported. Concomitant therapies included anti-thymocyte globulin (ATG) (induction). On an unknown date, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) 40 mcg/mL, 3 dosage regimen (0, 1, 6 months) (RECOMBIVAX HB) (route of administration, vaccination site, vaccination scheme, lot #, and expiration date were not reported) as a prophylaxis. On an unknown date (Posttransplant HBV vaccine completion), the hepatitis B surface antigen (HBsAb) testing was minor to 10 IU/L (vaccination failure). At the reporting time, the outcome of was unknown. The reporter considered the event of vaccination failure to be related to Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB). This is one case of several received from the same literature article. Lot # is being requested and will be submitted if received.
Medical History/Concurrent Conditions: Lung transplant
Test Name: HBsAb; Result Unstructured Data: Minor to 10 IU/L